Follow
Anders N. Kristoffersson
Anders N. Kristoffersson
Consultant, Pharmetheus AB
Verified email at pharmetheus.com
Title
Cited by
Cited by
Year
Simulation-based evaluation of PK/PD indices for meropenem across patient groups and experimental designs
AN Kristoffersson, P David-Pierson, NJ Parrott, O Kuhlmann, T Lave, ...
Pharmaceutical research 33, 1115-1125, 2016
642016
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: In vitro synergism is not associated with better clinical outcomes
A Nutman, J Lellouche, E Temkin, G Daikos, A Skiada, ...
Clinical Microbiology and Infection 26 (9), 1185-1191, 2020
572020
Semi-mechanistic pharmacokinetic–pharmacodynamic modelling of antibiotic drug combinations
MJE Brill, AN Kristoffersson, C Zhao, EI Nielsen, LE Friberg
Clinical Microbiology and Infection 24 (7), 697-706, 2018
532018
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant …
Y Dickstein, L Leibovici, D Yahav, N Eliakim-Raz, GL Daikos, A Skiada, ...
BMJ open 6 (4), e009956, 2016
512016
Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model
AF Mohamed, AN Kristoffersson, M Karvanen, EI Nielsen, O Cars, ...
Journal of Antimicrobial Chemotherapy 71 (5), 1279-1290, 2016
452016
Population pharmacokinetics of piperacillin in sepsis patients: should alternative dosing strategies be considered?
MG Andersen, A Thorsted, M Storgaard, AN Kristoffersson, LE Friberg, ...
Antimicrobial agents and chemotherapy 62 (5), 10.1128/aac. 02306-17, 2018
442018
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria
AN Kristoffersson, V Rognås, MJE Brill, Y Dishon-Benattar, ...
Clinical Microbiology and Infection 26 (12), 1644-1650, 2020
232020
Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?
SF Maarbjerg, A Thorsted, A Kristoffersson, LE Friberg, EI Nielsen, ...
Pediatric blood & cancer 66 (6), e27654, 2019
182019
A novel mechanism-based pharmacokinetic–pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria
AN Kristoffersson, C Bissantz, R Okujava, A Haldimann, I Walter, T Shi, ...
Journal of Antimicrobial Chemotherapy 75 (2), 400-408, 2020
162020
Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
A Thorsted, AN Kristoffersson, SF Maarbjerg, H Schrøder, M Wang, ...
Journal of Antimicrobial Chemotherapy 74 (10), 2984-2993, 2019
122019
Inter occasion variability in individual optimal design
AN Kristoffersson, LE Friberg, J Nyberg
Journal of Pharmacokinetics and Pharmacodynamics 42, 735-750, 2015
92015
Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli
DD Khan, P Lagerbäck, C Malmberg, AN Kristoffersson, E Wistrand-Yuen, ...
International journal of antimicrobial agents 51 (3), 399-406, 2018
62018
Study Design and Dose Regimen Evaluation of Antibiotics based on Pharmacokinetic and Pharmacodynamic Modelling
A Kristoffersson
Acta Universitatis Upsaliensis, 2015
52015
Bounded integer model‐based analysis of psoriasis area and severity index in patients with moderate‐to‐severe plaque psoriasis receiving BI 730357
QX Ooi, A Kristoffersson, J Korell, M Flack, E L. Plan, B Weber
CPT: Pharmacometrics & Systems Pharmacology, 2023
22023
Optimal design (OD) and in vitro validation of reduced time–kill curve experiments for pharmacokinetic-pharmacodynamic (PK/PD) modeling
AN Kristoffersson, LE Friberg
Fifty-fourth Interscience Conference on Antimicrobial Agents and …, 2014
22014
Optimal design of in vitro time kill curve experiments for the evaluation of antibiotic effects
A Kristoffersson, AC Hooker, MO Karlsson, LE Friberg
20th Population Approach Group Europe (PAGE) Meeting, 0
1
Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model
C Zhao, AN Kristoffersson, DD Khan, P Lagerbäck, U Lustig, S Cao, ...
2023
Erratum to: Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen
A Thorsted, AN Kristoffersson, SF Maarbjerg, H Schrøder, M Wang, ...
Journal of Antimicrobial Chemotherapy 75 (1), 254-255, 2020
2020
Suboptimal Piperacillin-Exposure Following Bolus Administration in Children with Chemotherapy-Induced Fever
SF Maarbjerg, AN Kristoffersson, LE Friberg, B Brock, H Schroder
Pediatric Blood and Cancer 65 (2), S524, 2018
2018
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant …
Y Dickstein, L Leibovici, D Yahav, N Eliakim-Raz, GL Daikos, A Skiada, ...
2016
The system can't perform the operation now. Try again later.
Articles 1–20